TABLE 1.
Median (n = 3) MICSCFM2 of tobramycin (μg/ml) for the different P. aeruginosa PAO1 lineages
| Lineage + treatmenta | Cycle 0 | Cycle 5 | Cycle 10 | Cycle 16 |
|---|---|---|---|---|
| L1 TOB | 10 | 10 | 20 | 40 |
| L2 TOB | 10 | 10 | 10 | 40 |
| L3 TOB | 10 | 10 | 40 | 40 |
| L1 TOB + C-30 | 10 | 40 | 40 | 80 |
| L2 TOB + C-30 | 10 | 80 | 80 | 80 |
| L3 TOB + C-30 | 10 | 80 | 40 | 80 |
| L1 C-30 | 10 | 10 | 10 | 10 |
| L2 C-30 | 10 | 10 | 10 | 10 |
| L3 C-30 | 10 | 10 | 10 | 10 |
L1, lineage 1; L2, lineage 2; L3, lineage 3; TOB, treatment with tobramycin alone; C-30, treatment with the QSI C-30 alone; TOB + C-30, treatment with both together.